Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the
current estimate of overall survival as a study endpoint prior to launching the blinded
randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug
combination will also be evaluated.